City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Kemp H Kernstine, MD, PhD  
Search results:  2  Clinical trial(s) found  (Page 1 of 1 )
 
Click here to generate a printer-friendly view  
 09157
   P.I.: Kemp Kernstine, MD, PhD
Title: SWOG; S0720: Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Lung Cancer (NSCLC)
 06068
   P.I.: Kemp Kernstine, MD, PhD
Title: OSI Radiant: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR Positive Tumors
 
Click here for  Full Eligibility Criteria
 

  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.